Clinical Trial

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2023 (before its estimated August 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06010667
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Epithelial Ovarian Cancer
Enrollment 60 participants
Start Date 2023-09-01
Primary Completion 2024-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-08-24